{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:55:37Z","timestamp":1762955737845,"version":"3.41.2"},"reference-count":13,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1097\/igc.0000000000001069","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T14:03:48Z","timestamp":1499868228000},"page":"1794-1801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer"],"prefix":"10.1016","volume":"27","author":[{"given":"Dhammapoj","family":"Jeerakornpassawat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prapaporn","family":"Suprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/IGC.0000000000001069_bb0005","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/CAD.0000000000000057","article-title":"Taxanes: their impact on gynecologic malignancy","volume":"25","author":"Schwab","year":"2014","journal-title":"Anticancer Drugs."},{"key":"10.1097\/IGC.0000000000001069_bb0010","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med."},{"key":"10.1097\/IGC.0000000000001069_bb0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol."},{"key":"10.1097\/IGC.0000000000001069_bb0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1008207025430","article-title":"Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions","volume":"8","author":"Bookman","year":"1997","journal-title":"Ann Oncol."},{"key":"10.1097\/IGC.0000000000001069_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ajco.12495","article-title":"Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: a double-blind randomized controlled trial","volume":"12","author":"Yanaranop","year":"2016","journal-title":"Asia Pac J Clin Oncol."},{"key":"10.1097\/IGC.0000000000001069_bb0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet."},{"key":"10.1097\/IGC.0000000000001069_bb0035","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/IGC.0b013e31829f1799","article-title":"Intravenous versus oral dexamethasone premedication in preventing paclitaxel infusion hypersensitivity reactions in gynecological malignancies","volume":"23","author":"O\u2019Cathail","year":"2013","journal-title":"Int J Gynecol Cancer."},{"key":"10.1097\/IGC.0000000000001069_bb0040","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol."},{"key":"10.1097\/IGC.0000000000001069_bb0045","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2003, as modified 2006. Available at: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed September 26, 2016."},{"key":"10.1097\/IGC.0000000000001069_bb0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s10147-007-0675-9","article-title":"Preliminary experience with a modified premedication protocol that included intravenous diphenhydramine and calcium bromide for the prophylaxis of paclitaxel-related hypersensitivity reactions","volume":"12","author":"Sasada","year":"2007","journal-title":"Int J Clin Oncol."},{"key":"10.1097\/IGC.0000000000001069_bb0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1006\/gyno.1998.4993","article-title":"Single-dose dexamethasone paclitaxel premedication","volume":"69","author":"Micha","year":"1998","journal-title":"Gynecol Oncol."},{"key":"10.1097\/IGC.0000000000001069_bb0060","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1345\/aph.10287","article-title":"Prophylaxis for paclitaxel hypersensitivity reactions","volume":"35","author":"Kintzel","year":"2001","journal-title":"Ann Pharmacother."},{"key":"10.1097\/IGC.0000000000001069_bb0065","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/gyno.1995.1274","article-title":"Adrenal function following high-dose steroids in ovarian cancer patients","volume":"59","author":"Del Priore","year":"1995","journal-title":"Gynecol Oncol."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2408962X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2408962X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/Insights.ovid.com\/crossref?an=00009577-201710000-00032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:18:55Z","timestamp":1753222735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2408962X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S1048891X2408962X"],"URL":"https:\/\/doi.org\/10.1097\/igc.0000000000001069","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, Controlled Trial of Dexamethasone Versus Dexamethasone Plus Hydrocortisone as Prophylaxis for Hypersensitivity Reactions Due to Paclitaxel Treatment for Gynecologic Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1097\/IGC.0000000000001069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright Copyright \u00a9 2017 by IGCS and ESGO.","name":"copyright","label":"Copyright"}]}}